TEVA
Teva Pharma Industries Ltd ADR
NYSE: TEVA · HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC
$35.38
+11.89% today
Updated 2026-04-29
Market cap
$41.20B
P/E ratio
26.40
P/S ratio
2.39x
EPS (TTM)
$1.34
Dividend yield
—
52W range
$15 – $37
Volume
6.7M
Teva Pharma Industries Ltd ADR (TEVA) Earnings
Quarterly earnings history, analyst estimates, and stock price reaction.
EPS beat streak
6 of 8
Last 8 quarters
Avg EPS surprise
+20.9%
Last 4 quarters
Revenue YoY growth
+11.4%
Most recent quarter
EPS YoY growth
+35.2%
Most recent quarter
Earnings surprise history (last 12 quarters)
Beat estimate Missed estimate
Quarterly EPS and revenue trend
Quarterly revenue EPS (diluted)
How the stock reacts to earnings
Avg 1-day reaction
+4.9%
Last 3 reports
Positive reaction rate
67%
2 of 3 quarters
Largest single-day move
+19.6%
2025-11-05
| Report date | EPS actual | Surprise | Close before | Close after | 1-day reaction |
|---|---|---|---|---|---|
| 2026-01-28 | $0.96 | +47.7% | $32.53 | $33.07 | +1.7% |
| 2025-11-05 | $0.78 | +16.4% | $20.46 | $24.46 | +19.6% |
| 2025-07-30 | $0.66 | +6.5% | $16.54 | $15.45 | -6.6% |
Quarterly earnings history
| Fiscal quarter ending | EPS estimate | EPS actual | Surprise | Revenue | YoY revenue |
|---|---|---|---|---|---|
| 2025-12-31 | $0.65 | $0.96 | +47.7% | $4.71B | +11.4% |
| 2025-09-30 | $0.67 | $0.78 | +16.4% | $4.48B | +3.4% |
| 2025-06-30 | $0.62 | $0.66 | +6.5% | $4.18B | +0.3% |
| 2025-03-31 | $0.46 | $0.52 | +13.0% | $3.89B | +1.9% |
| 2024-12-31 | $0.70 | $0.71 | +1.4% | $4.23B | -5.1% |
| 2024-09-30 | $0.66 | $-0.39 | -159.1% | $4.33B | +12.5% |
| 2024-06-30 | $0.55 | $0.61 | +10.9% | $4.16B | +7.4% |
| 2024-03-31 | $0.51 | $0.48 | -5.9% | $3.82B | — |
| 2023-12-31 | $0.77 | $1.00 | +29.9% | $4.46B | — |
| 2023-09-30 | $0.61 | $0.60 | -1.6% | $3.85B | — |
| 2023-06-30 | $0.53 | $0.56 | +5.7% | $3.88B | — |
Analyst EPS and revenue estimates for upcoming years
| Period | EPS estimate | Revenue estimate | Revenue growth | Analysts | Confidence |
|---|---|---|---|---|---|
| 2026 (E) | $2.76 | $17.1B | +-0.9% | 8 | high |
| 2027 (E) | $3.18 | $17.9B | +4.4% | 8 | high |
| 2028 (E) | $3.65 | $18.6B | +4.4% | 8 | medium |
| 2029 (E) | $4.12 | $19.7B | +5.5% | 8 | medium |
| 2030 (E) | $4.68 | $20.9B | +6.1% | 8 | medium |
Frequently asked questions
Has Teva Pharma Industries Ltd ADR beaten earnings estimates?
Teva Pharma Industries Ltd ADR has beaten Wall Street EPS estimates in 6 of its last 8 quarterly reports, with an average EPS surprise of +20.9% over the last 4 quarters.
How does TEVA stock react to earnings?
TEVA stock has moved an average of +4.9% in the trading day following earnings over its last 3 reports, with positive reactions in 67% of those quarters.
What is Teva Pharma Industries Ltd ADR's revenue growth rate?
Teva Pharma Industries Ltd ADR reported year-over-year revenue growth of +11.4% in its most recent quarter, with EPS growing +35.2% year-over-year.
What is the expected EPS for TEVA in 2026?
Analysts expect Teva Pharma Industries Ltd ADR to report EPS of $2.76 for fiscal year 2026, on revenue of $17.1B, based on estimates from 8 analysts.